What is EnteroBiotix?
EnteroBiotix is a clinical-stage biopharmaceutical company dedicated to establishing a leadership position in the field of full-spectrum microbiome therapeutics. The company's flagship product, EBX-102-02, is a promising candidate for treating irritable bowel syndrome, with the potential to be the first disease-modifying therapy for the condition. Following encouraging Phase 2a results from the TrIuMPH trial, EBX-102-02 is now advancing into Phase 2b development through the RISE trial, marking a critical step in its clinical progression.
How much funding has EnteroBiotix raised?
EnteroBiotix has raised a total of $91.6M across 7 funding rounds:
Angel/Seed
$4M
Series A
$21.5M
Debt
$14.6M
Private Equity
$19.8M
Private Equity
$1.4M
Private Equity
$5.3M
Unspecified
$25M
Angel/Seed (2019): $4M with participation from Fund Twenty8, Gabriel, NCIMB, Equity Gap, Bank Workers Charity, University of Aberdeen, Scottish Enterprise, Barwell, Syndicate Room, and SIS Ventures
Series A (2021): $21.5M led by SIS Ventures, Kineticos Ventures, Scottish Enterprise, and Thairm Bio
Debt (2024): $14.6M supported by Scottish National Investment Bank
Private Equity (2024): $19.8M featuring Kineticos
Private Equity (2025): $1.4M, investors not publicly disclosed
Private Equity (2026): $5.3M, investors not publicly disclosed
Unspecified (2026): $25M led by Scottish National Investment Bank
Key Investors in EnteroBiotix
Scottish National Investment Bank
The Scottish National Investment Bank is a development investment bank focused on providing long-term capital for businesses and projects across Scotland, aiming to foster a fairer and more sustainable economy through public and private investments. It prioritizes climate change, community transformation, and innovation.
Kineticos
Kineticos is a management consulting firm specializing in the life science industry, offering expertise in corporate strategy, sales, marketing, operational execution, and technology innovation. Founded in 2007, it is based in Morrisville, North Carolina.
SIS Ventures
SIS Ventures, part of Social Investment Scotland, invests in impact-led enterprises addressing societal challenges, providing mission-aligned finance to accelerate the success of socially and environmentally focused businesses.
What's next for EnteroBiotix?
The recent major strategic investment signals a strong vote of confidence in EnteroBiotix's therapeutic pipeline and its potential to address significant unmet needs in gastroenterology. This capital infusion is expected to fuel the ongoing RISE trial and support further research and development initiatives. As EnteroBiotix moves through advanced clinical stages, the company is strategically positioned to advance its pipeline, potentially leading to commercialization and a significant impact on patient care within the microbiome therapeutics market.
See full EnteroBiotix company page
